Study details
Enrolling now
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Gilead Sciences
NCT IDNCT06029972ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
176
Study length
about 3.5 years
Ages
18–75
Locations
53 sites in AZ, CA, FL +12
What this study is about
This trial is testing if tilpisertib fosmecarbil, a medication, can help people with moderately to severely active ulcerative colitis. It compares participants treated with tilpisertib fosmecarbil to those treated with a placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Tilpisertib Fosmecarbil
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Body systems
Gastroenterology